OpenAlex
PricingAboutJobs
Log inGet started
Work

Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome—positive acute lymphoblastic leukemia

HTML

Year: 2007
Type: article
Source: Clinical Therapeutics
DOI: 10.1016/j.clinthera.2007.11.005
Author: Michael Steinberg
Institution: Massachusetts College of Pharmacy and Health Sciences
Language: English

Topic: Chronic Myeloid Leukemia Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: dasatinib, tyrosine kinase inhibitors, chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, BCR-ABL, imatinib resistance, BCR-ABL mutations, START trial, pharmacokinetics, adverse effects, cytogenetic response, hematologic response, chronic phase CML, blast crisis, accelerated phase CML, imatinib, dasatinib resistance
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2162720854
FWCI: 7.913
Cites: 51
Cited by: 231
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security